SCAI 2026 Workshop on the Treatment of Pulmonary Embolism-Panel Discussion 1

Video Transcription

Video Summary

The discussion focused on HyPytho and related PE trials, especially why mortality benefits may not appear even if treatment prevents clinical deterioration. Speakers argued this is a design issue: patients who worsen are rapidly rescued, making death less likely in trial settings. They emphasized that clinical deterioration itself is a meaningful outcome, not just a surrogate. The group also noted how difficult HyPytho was to enroll, with strict criteria and many patients already clinically “crumping.”  <br /><br />They then debated how these results should influence practice and future guidelines. There was broad agreement that intermediate-high-risk PE benefits from treatment, but the best therapy remains uncertain. Opinions ranged from catheter-directed lysis to thrombectomy and combination approaches, with a trend toward more thrombectomy as technology improves.  <br /><br />Finally, they discussed workforce strain in PE response teams and suggested better triage, tiered call systems, AI support, and stronger outpatient PE follow-up clinics to reduce burnout and improve care.

Asset Caption

closed captions are computer-generated

Keywords

HyPytho

pulmonary embolism

clinical deterioration

thrombectomy

PE response teams